Research programme: AGE Formation Inhibitors - Synvista

Drug Profile

Research programme: AGE Formation Inhibitors - Synvista

Alternative Names: ALT-946

Latest Information Update: 07 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alteon
  • Developer Synvista Therapeutics
  • Class Acetamides; Antihyperglycaemics; Hydrazines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 24 Jul 2007 Alteon is now called Synvista Therapeutics
  • 22 Nov 2002 A preclinical study has been added to the Diabetes pharmacodynamics section
  • 08 May 2001 Preclinical development for Diabetic nephropathies in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top